medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2004, Number 1

<< Back Next >>

Ann Hepatol 2004; 3 (1)

Etiology of Liver Cirrhosis in Mexico

Méndez-Sánchez N, Aguilar-Ramírez JR, Reyes A, Dehesa M, Juárez A, Castañeda B, Sánchez-Avila F, Poo JL, Guevara GL, Lizardi J, Valdovinos MA, Uribe M, Contreras AM, Tirado P, Aguirre J, Rivera-Benítez C, Santiago-Santiago R, Bosques-Padilla F, Muñoz L, Guerrero A, Ramos M, Rodríguez-Hernández H, Jacobo-Karam J

Language: English
References: 29
Page: 30-33
PDF size: 62.44 Kb.


Text Extraction

Background: In the last decades it has been suggested that the main cause of liver cirrhosis in Mexico is alcohol. Currently in Western countries hepatitis C virus (HCV) infection is one of the leading causes of end-stage liver disease and liver transplantation. In Mexico, we have no data relative to the etiology of liver cirrhosis. The aim of this study was to investigate the main causes of liver cirrhosis in Mexico.
Methods: Eight hospitals located in different areas of the country were invited to participate in this study. Those hospitals provide health care to different social classes of the country. The inclusion criteria were the presence of either an histological or a clinical and biochemical diagnosis of liver cirrhosis.
Results: A total of 1,486 cases were included in this study. The etiology of liver cirrhosis was alcohol in 587 (39.5%), HCV 544 (36.6%), cryptogenic 154 (10.4%), PBC 84 (5.7), HBV 75 (5.0%) and other 42 (2.8). There was not statistical difference between alcohol and HCV.
Conclusions: We conclude that the main causes of liver cirrhosis in Mexico are alcohol and HCV.


REFERENCES

  1. Méndez-Sánchez N. Enfermedad Hepática por alcohol. En: Méndez-Sánchez N y Uribe M. Conceptos Actuales en Hepatología. 1ª Edición, Masson-Doyma. México, 2003.

  2. Keeffe EB. Liver transplantation: current status and novel approaches to liver replacement. Gastroenterology 2001; 120: 749-762.

  3. Di Bisceglie AM. Natural history of hepatitis C: its impact on clinical management. Hepatology 2000; 31: 1014-1018.

  4. Bellentani S, Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol 2001; 35: 531-7.

  5. Frenk J, Lozano R, González M. Economía y salud: propuesta para el avance de salud en México. Informe final. México, D.F.: Fundación Mexicana para la Salud, 1994.

  6. Campollo O, Valencia-Salinas JJ, Berumen-Arellano A, Perez-Aranda MA, Panduro-Cerda A, Segura-Ortega J. Epidemiological characteristics of liver cirrhosis at the Hospital Civil of Guadalajara. Salud Publica Mex 1997; 39: 195-200.

  7. Anthony PP, Ishak KG, Nayak NC, Poulsen HE, Scheuer PJ, Sobin LH. The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization. Clin Pathol 1978; 31: 395-414.

  8. Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice British Society of Gastroenterology. Gut 1999; 45 Suppl 4: IV1-IV11.

  9. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II. Addiction 1993; 88: 791-804.

  10. Winer BJ. Statistical principles in experimental design. 2nd ed. New York: McGraw-Hill; 1971.

  11. Secretaría de Salud. Mortalidad 1999, México, DF: SSA, 1999.

  12. Narro-Robles J, Gutierrez-Avila JH, Lopez-Cervantes M, Borges G, Rosovsky H. Liver cirrhosis mortality in Mexico. II. Excess mortality and pulque consumption. Salud Publica Mex 1992; 34: 388-405.

  13. Narro-Robles J, Gutierrez-Avila JH. Ecological correlation between consumption of alcoholic beverages and liver cirrhosis mortality in Mexico. Salud Publica Mex 1997; 39: 217-20.

  14. World Health Organization. Hepatitis C: global prevalence. Wkly Epidemiol Rep 1997: 341-8.

  15. El-Sayed NM, Gomatos PJ, Rodier GR, Wierzba TF, Darwish A, Khashaba S, et al. Seroprevalence survey of Egyptian tourism workers for hepatitis B virus, hepatitis C virus human immunodeficiency virus and Treponema pallidum infections: association of hepatitis C virus infections with specific regions of Egypt. Am J Trop Med Hyg 1996; 55: 179-184.

  16. Nakashima K, Ikematsu H, Hayashi J, Kishihara Y, Mutsutake A, Kashiwagi S. Intrafamilial transmission of hepatitis C virus among the population of an endemic area of Japan. JAMA 1995; 274: 1459-61.

  17. Osella AR, Misciagna G, Leone A, DiLeo A, Fiore G. Epidemiology of hepatitis C virus infection in an area of southern Italy. J Hepatol 1997; 27: 30-5.

  18. Uribe M, Méndez-Sánchez N. Hepatitis C in Mexico. Rev Gastroenterol Méx 2002; 67 (Supl. 2): 7-8.

  19. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment and prevention of hepatitis C. Ann Intern Med 2000; 132: 296-305, 37.

  20. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000; 20: 17-35.

  21. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-472.

  22. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80.

  23. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22: 1714-1719.

  24. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathologic severity. Gastroenterology 1999; 116: 1413–1419.

  25. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-40.

  26. Méndez-Sánchez N y Uribe M. OBESIDAD. Epidemiología, Fisiopatología y Manifestaciones Clínicas. El Manual Moderno, México 2002.

  27. Ruiz-Arguelles GJ, Garces-Eisele J, Gelbart T, Monroy-Barreto M, Reyes-Nunez V, Juarez-Morales JL, de Lourdes Gonzalez-Garrido M, Ramirez-Cisneros FJ, Gallegos-Antunez D. Analysis of HFE-codon 63/282 (H63D/C282Y) gene variants in mexican mestizos. Blood donors and patients with hereditary hemochromatosis. Arch Med Res 2000; 31: 422-4.

  28. Smith BN, Kantrowitz W, Grace ND, Greenberg MS, Patton TJ, Ookubo R, Sorger K, Semeraro JG, Doyle JR, Cooper AG, Kamat BR, Maregni LM, Rand WM. Prevalence of hereditary hemochromatosis in a Massachusetts corporation: is Celtic origin a risk factor? Hepatology 1997; 25: 1439-1446.

  29. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997; 34: 275-278.




2020     |     www.medigraphic.com